StockData
Immunovant, Inc. logo

Immunovant, Inc. (IMVT) stock

IMVTNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends March 31
Financials through Q1 FY2027, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 6/30
$33.21−0.07 (-0.21%)

Close on Nov 17, 2026Market cap $6.86BP/E –Yield –

Immunovant total assets

Total assets on the balance sheet at the end of each period.

Immunovant's total assets was $852.49M at Jun 30, 2026. For fiscal 2026 it was $957.01M, up 23.3% from the year before. The highest annual figure on record is $957.01M in fiscal 2026.

Annual total assets

PeriodPeriod endValueChange
FY2026Mar 31, 2026$957.01M+23.3%
FY2025Mar 31, 2025$776.22M+16.5%
FY2024Mar 31, 2024$666.37M+64.2%
FY2023Mar 31, 2023$405.84M-21.3%
FY2022Mar 31, 2022$515.56M+25.0%
FY2021Mar 31, 2021$412.49M+277.1%
FY2020Mar 31, 2020$109.39M+691.1%
FY2019Mar 31, 2019$13.83M–

Quarterly total assets

Change is against the same quarter a year earlier.

Periods
PeriodPeriod endValueChange
Q1 FY2027CQ2 2026Jun 30, 2026$852.49M+28.9%
Q4 FY2026CQ1 2026Mar 31, 2026$957.01M+23.3%
Q3 FY2026CQ4 2025Dec 31, 2025$1.05B+150.0%
Q2 FY2026CQ3 2025Sep 30, 2025$582.96M+13.0%
Q1 FY2026CQ2 2025Jun 30, 2025$661.44M+12.2%
Q4 FY2025CQ1 2025Mar 31, 2025$776.22M+16.5%
Q3 FY2025CQ4 2024Dec 31, 2024$420.93M-40.8%
Q2 FY2025CQ3 2024Sep 30, 2024$515.71M+76.6%
Q1 FY2025CQ2 2024Jun 30, 2024$589.68M+67.9%
Q4 FY2024CQ1 2024Mar 31, 2024$666.37M+64.2%
Q3 FY2024CQ4 2023Dec 31, 2023$711.45M+55.9%
Q2 FY2024CQ3 2023Sep 30, 2023$292.07M-31.8%
Q1 FY2024CQ2 2023Jun 30, 2023$351.22M-23.4%
Q4 FY2023CQ1 2023Mar 31, 2023$405.84M-21.3%
Q3 FY2023CQ4 2022Dec 31, 2022$456.24M-16.0%
Q2 FY2023CQ3 2022Sep 30, 2022$428.15M-24.5%
Q1 FY2023CQ2 2022Jun 30, 2022$458.66M+18.2%
Q4 FY2022CQ1 2022Mar 31, 2022$515.56M+25.0%
Q3 FY2022CQ4 2021Dec 31, 2021$543.18M+25.4%
Q2 FY2022CQ3 2021Sep 30, 2021$566.73M+24.9%
Q1 FY2022CQ2 2021Jun 30, 2021$388.03M+33.7%
Q4 FY2021CQ1 2021Mar 31, 2021$412.49M+277.1%
Q3 FY2021CQ4 2020Dec 31, 2020$433.03M+267.6%
Q2 FY2021CQ3 2020Sep 30, 2020$453.90M+286.6%
Q1 FY2021CQ2 2020Jun 30, 2020$290.29M+1999.3%
Q4 FY2020CQ1 2020Mar 31, 2020$109.39M+26909.1%
Q3 FY2020CQ4 2018Sep 30, 2019$117.79M–
Q1 FY2020CQ2 2019Jun 30, 2019$117.42M–
Q4 FY2019CQ1 2019Mar 31, 2019$13.83M–
Q3 FY2019CQ4 2018Dec 31, 2018$405.00K–

More Immunovant figures

See a number that looks wrong?